- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04329650
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia
Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Badalona, Spain
- Hospital Germans Trias i Pujol
-
Barcelona, Spain, 08036
- Hospital Clínic de Barcelona
-
Salamanca, Spain
- Hospital Universitario de Salamanca
-
Terrassa, Spain
- Hospital Universitari Mutua de Terrassa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years old.
Hospitalized patient (or documentation of a hospitalization plan if the patient is in an emergency department) with illness of more than 5 days of duration with evidence of pneumonia by chest radiography / tomography computed chest and meets at least one of the following requirements:
- Non-critical patient with pneumonia in radiological progression and / or
- Patient with progressive respiratory failure
- Laboratory confirmed SARS-CoV-2 infection (by PCR) or other commercialized analysis or public health in any sample collected 4 days before the randomization or COVID-19 criteria following the defined diagnostic criteria at that time in the center.
- Be willing and able to comply with the study related procedures / evaluations.
- Women of childbearing potential * should have a negative serum pregnancy test before enrollment in the study and must commit to using methods highly effective contraceptives (intrauterine device, bilateral tubal occlusion, vasectomized couple and sexual abstinence).
- Written informed consent. In case of inability of the patient to sign the informed consent, a verbal informed consent from the legal representative or family witness (or failing this, an impartial witness outside the investigator team) will be obtained by phone.
When circumstances so allow, participants should sign the consent form. The confirmation of the verbal informed consent will be documented in a document as evidence that verbal consent has been obtained.
Exclusion Criteria:
- Patient who, in the investigator's opinion, is unlikely to survive> 48 hours after the inclusion in the study.
Presence of any of the following abnormal analytical values at the time of the inclusion in the study:
- absolute neutrophil count less than 2000 / mm3;
- AST or ALT> 5 times the upper limit of normality;
- platelets <50,000 per mm3.
- Patients with respiratory support greater than or equal to 60%
- In active treatment with immunosuppressants or previous prolonged treatment (more 3 months) of oral corticosteroids for a disease not related to COVID-19 at a dose greater than 10 mg of prednisone or equivalent per day.
- Known active tuberculosis or known history of tuberculosis uncompleted treatment.
- Patients with active systemic bacterial and / or fungal infections.
- Patients who have received previous treatment with IL6 inhibitor (tocilizumab, sarilumab).
- Participants who, at the investigator's discretion, are not eligible to participate, regardless of the reason, including medical or clinical conditions, or participants potentially at risk of not following study procedures.
- Patients who do not have entry criteria in the Intensive Care Unit.
- Pregnancy or lactation.
- Known hypersensitivity to siltuximab or to any of its excipients (histidine, histidine hydrochloride, polysorbate 80 and sucrose).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Siltuximab 11mg/Kg
|
A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
|
Active Comparator: Dexamethasone 6mg/24h
|
A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients requiring ICU admission at any time within the study period.
Time Frame: 29 days
|
29 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Days of stay in the ICU during the study period.
Time Frame: 29 days
|
29 days
|
Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.
Time Frame: 29 days
|
29 days
|
Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.
Time Frame: 29 days
|
29 days
|
Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients using mechanical ventilation at 29 days.
Time Frame: 29 days
|
29 days
|
Days with use of mechanical ventilation at 29 days.
Time Frame: 29 days
|
29 days
|
Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.
Time Frame: 29 days
|
29 days
|
Days of hospitalization among survivors at 29 days.
Time Frame: 29 days
|
29 days
|
Mortality rate from any cause at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients with serious adverse events at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients with gastrointestinal perforation at 29 days.
Time Frame: 29 days
|
29 days
|
Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.
Time Frame: 29 days
|
29 days
|
Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.
Time Frame: Days 1, 3, 5, 7 and 9
|
Days 1, 3, 5, 7 and 9
|
Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.
Time Frame: Days 1, 3, 5, 7 and 9
|
Days 1, 3, 5, 7 and 9
|
Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.
Time Frame: Days 1, 3, 5, 7 and 9
|
Days 1, 3, 5, 7 and 9
|
Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.
Time Frame: Days 1, 3, 5, 7 and 9
|
Days 1, 3, 5, 7 and 9
|
Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.
Time Frame: Days 1, 3, 5, 7 and 9
|
Days 1, 3, 5, 7 and 9
|
Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.
Time Frame: Days 1, 3, 5, 7 and 9
|
Days 1, 3, 5, 7 and 9
|
Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.
Time Frame: Days 1, 3, 5, 7 and 9
|
Days 1, 3, 5, 7 and 9
|
Changes from baseline in chest Rx at days 1, 3 and 5.
Time Frame: Days 1, 3 and 5
|
Days 1, 3 and 5
|
Analysis of genetic variants in CYP enzymes and transporters SLCO1B1, ABCCs and ABCB1 to the response to the study treatments.
Time Frame: 29 days
|
29 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Felipe García, MD, Hospital Clinic of Barcelona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Lung Diseases
- COVID-19
- Pneumonia
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
- Siltuximab
Other Study ID Numbers
- SILCOR-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Siltuximab
-
Carla Greenbaum, MDJanssen Research & Development, LLCCompleted
-
Centocor, Inc.CompletedLymphoma, Non-Hodgkin | Multiple Myeloma | Giant Lymph Node HyperplasiaUnited States
-
Janssen Research & Development, LLCCompletedHigh-risk Smoldering Multiple MyelomaUnited States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
-
Janssen Research & Development, LLCCompletedMultiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell NeoplasmUnited States, Belgium, Russian Federation
-
University of Alabama at BirminghamRecruitingLymphoma, Non-Hodgkin | Multiple Myeloma | Acute Lymphoblastic Leukemia | Cytokine Release Syndrome | ICANSUnited States
-
Janssen Research & Development, LLCCompletedMulticentric Castleman's DiseaseUnited States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Israel, Korea, Republic of, Singapore, Brazil, Belgium, New Zealand, Norway, Egypt, Hong Kong
-
Centocor, Inc.Completed
-
EusaPharma (UK) LimitedTerminatedIdiopathic Multicentric Castleman's DiseaseUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteEUSA Pharma, Inc.RecruitingLarge Granular Lymphocyte LeukemiaUnited States
-
Centocor, Inc.CompletedCarcinoma, Renal CellFrance, United Kingdom, Netherlands, Czech Republic